Beta cell regeneration therapy for type 1 diabetes by GLP-1 receptor agonist and insulin

Beta cell regeneration therapy for type 1 diabetes by GLP-1 receptor agonist and insulin - Beta cell regeneration therapy for type 1 diabetes by GLP-1 receptor agonist and insulin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006088

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes

Interventions

Type 1 diabetes. Liraglutide 0.9 mg/day (0.3 mg/day at the beginning and increased by 0.3 mg/day with one week interval up to 0.9 mg/day) . The trial period is 24 months. Throughout the trial pe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Type 1 diabetes. -Diagnosis of Type 1 diabetes is made by the criteria of the Japan Diabetes Society -20-59 years of age -Less than 2 years with type 1 diabetes

Exclusion criteria

Exclusion criteria: -History or presence of heart failure -Presence of severe hepatic or/and renal dysfunction -History or presence of alcoholic or severe infectious disease -Pregnancy -Other inappropriate patients judged by doctor

Design outcomes

Primary

Measure	Time frame
Area under the curve of 2-hour serum C-peptide in mixed-meal test Serum C-peptide levels by glucagon stimulation test	—

Secondary

Measure	Time frame
Glycated hemoglobin and glycated albumin Total daily insulin dosage	—

Countries

Japan

Contacts

Public ContactAkihisa Imagawa

Osaka University Graduate School of Medicine Department of Metabolic Medicine

aimagawa@endmet.med.osaka-u.ac.jp06-6879-3732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026